TearScience®, Inc., a privately-held medical device company, today announced the promotion of Nicole Wicker to chief financial officer (CFO). Nicole has served as TearScience's vice president of finance since joining the company in December, 2008.
"Nicole played a critical role in raising the funding that TearScience needed to commercialize our breakthrough evaporative dry eye treatment," said Tim Willis, chief executive officer of TearScience. "Her success and broad financial management experience has been a tremendous asset to us. This promotion is well deserved. With Nicole's continued leadership, TearScience will be on solid financial ground during this next phase of rapid expansion."
In May, 2010, TearScience raised $44.5 million Series C financing, one of the largest med tech venture capital funding of 2010.
Nicole served as CFO for several companies and recently led the successful transition of companies from the startup stage through acquisition or initial public offering (IPO) including SmartPath and Motricity. Following graduation from the University of North Carolina, Chapel Hill, Nicole started her career with Ernst & Young in the Entrepreneurial Services group, where she worked 11 years and swiftly became lead financial executive in numerous SEC filings, IPOs, mergers and acquisitions, including Highwoods Properties, Divot Golf Corporation, BTI, General Parts, Intellikey, and Optometric Eye Care Center.
"TearScience is redefining how eye care physicians manage evaporative dry eye," added Wicker. "I'm very pleased to be part of such an important advance in the eye care industry that will help millions of dry eye sufferers."
TearScience manufactures and sells a complete system for eye care physicians to assess and treat patients for evaporative dry eye disease. The system is comprised of the LipiFlow® Thermal Pulsation System and the LipiView® Ocular Surface Interferometer. LipiFlow® heats and applies gentle pressure to a patient's eyelid in order to liquefy and evacuate obstructions in Meibomian glands during a 12-minute in-office procedure. The goal of unblocking the glands is to allow them to resume their natural production of lipids required for a healthy tear film.
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 86 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye's natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience's integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye, obstructed Meibomian glands. For additional information, visit www.tearscience.com.
# # #